Skip to main content

Rheumatoid Arthritis

Will a vegetarian diet and exercise actually help RA disease activity? At #ACR22, a Dutch program targeting a whole food plant-based diet, physical activity, and stress management has shown benefit in DAS28 RA disease activity measures. https://t.co/W2axkmbs3y https://t.co/5jktGiEk0T
Where are we with treating Pre-Rheumatoid Arthritis? Dr. Richard Conway ( @RichardPAConway ) discusses abstracts #0530, #1603 and #1604 shared at #ACR22.https://t.co/AagsZCyhSE https://t.co/K1RvdOMzvf
Vegetarian diet food nutrition

Will a vegetarian diet and exercise actually help RA disease activity?

Nov 25, 2022

The exact role of diet, physical activity, and stress management in the management of RA has long been debated. While reasonable evidence has supported the importance of physical activity in patients with RA, its capacity to reduce disease activity via conventional measures such as DAS28 was

Read Article
RA Topic Panel RheumNow recaps the best & most interesting data presented at #ACR22 in RA. Panelists: Drs.Conway, Najm, Liew, Pope, Segan Follow: @RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan https://t.co/GMqRmF2yXA https://t.co/WmYRTp49Rv
RA-ILD: an update Dr. Julian Segan ( @JulianSegan) discusses Abstract #1393 and Abstract #0245 presented at #ACR22.https://t.co/5Vk4NaWzqc https://t.co/doqhqeNgdX
steroids.prednisone.pills_.jpg

Steroids in RA: Friend or foe (or both)?

While have come so far from the days of our patients living on massive doses of steroids, we still have many patients who use steroids for our diseases, with increasing data for toxicity, even in low dose. As someone much smarter than me described them, steroids are our best frenemy.

Read Article
heart2.ekg_.red_.jpg

RA: MACE Events with Opioids vs. NSAIDs

Addressing chronic pain often leads general practitioners and specialists to prescribe opioids. However, opioids (weak and strong) have not demonstrated efficacy in long-term pain management; their chronic use could even worsen pain in users. Opioids prescription is often perceived as being

Read Article
Treatment Choices and Mortality in RA-ILD Dr. Julian Segan ( @JulianSegan) talks with Dr. Bryant England about abstract 0245 presented at #ACR22.https://t.co/5GTeZ6i43W https://t.co/t8E5TAJFxu
RA Topic Panel RheumNow recaps the best & most interesting data presented at #ACR22 in RA. Panelists: Drs.Conway, Najm, Liew, Pope, Segan Follow: @RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan https://t.co/6SAlQwcPS0 https://t.co/kSZgTQs6Ns
Infections in pre-RA: a cause or a consequence? Dr. Aurelie Najm ( @AurelieRheumo) discusses oral presentation abstract #0535 from #ACR22.https://t.co/ajI2zo4KRA https://t.co/cHkzNshVcn
Avoid Abatacept in RA patients with a history of cancer? Dr. Richard Conway ( @RichardPAConway ) discusses abstracts #0267 and #0255 presented at #ACR22. https://t.co/1lC33XlBt7 https://t.co/ttUQaTVF43
signs treat

Why treatment of pre-RA isn't ready for prime time

The ACR Great Debate was on "To treat or not to treat in pre-RA?". What is the clinician to do?

Read Article
RheumNow Podcast square

ACR 2022 Appraisal, Praise & Critique (11.18.2022)

Nov 18, 2022

It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle. 



I loved the city, but not the convention center (not easy to navigate). 



The meeting itself was very

Read Article
Lungs breathing

RA-ILD takes centre stage

Interstitial lung disease is common in RA, occurring in approximately 8% of RA patients. It is associated with a poor prognosis, and a median survival of 3 years. This important condition has often been neglected within the spectrum of RA research. That is changing, with excellent research

Read Article
Best of

ACR Best Abstracts - Day 3

Nov 14, 2022

The last day was jammed with important reports and research including the late breaking abstracts. 



 

Read Article
tumeric

The spicy topic of turmeric in rheumatoid arthritis

Nov 14, 2022

Curcumin, the active constituent of turmeric extract, has increasingly been promoted as a potential rheumatoid arthritis therapy, but data presented at ACR22 suggests that even in ideal situations, it is unable to do any better than placebo in replacing conventional RA therapies.

Read Article
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa
Which is better for CV risk in RA: triple therapy DMARDs or TNFi? TARGET study n=159 using PET/CT surrogate (endpoint responsiveness👀) - either led to benefit - both equally good - benefit *not* linked to change in DAS28 A direct CV effect of RA Rx? ABST2215 #ACR22 @RheumNow https://t.co/4FPvSbfGsD
Singh @NamrataRheum et al. Frailty in patients treated bDMARD/tsDMARD assoc serious infections aHR 1.34, any infection aHR 1.18, hospitalisation aHR 1.34 (all relative non-frail). @RheumNow #ACR22 Abstr#2218 https://t.co/ONsTBq8ehB https://t.co/iTVANh5flk
💤cognitive behavioural therapy 2 hours/wk for 6 wks for insomnia improves RA PROs at 26 wks Insomnia Severity Index -9.8 RAID -1.4 PGA -13 Small sample size wk6 trend improvement sleep efficiency 89% vs84% p=0.07 but not wk26https://t.co/rpKdtbREYs Abs#2188 #ACR22 @RheumNow https://t.co/kEBcPAdIKW
Peresolimab humanized IgG1 mab ➢ stimulates PD-1 & physiological immune inhibitory pathways ➢ In RA phase 2 study, superior to placebo at Week 12 DAS28/CDAI ➢ safety events were similar between treatment groups Emery P #L03 https://t.co/4Jd79CW5RA #ACR22 #ACRBest @RheumNow https://t.co/PSuLQgjYuz
Tonight at 7pm ET! Join our RA Topic Panel with panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, Julian Segan @RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan #ACR22https://t.co/hIH4WghLwN https://t.co/oKQbBnMiqQ
Sometimes your RA pts are eligible for ICI cancer immunotherapy, but there’s hesitancy because of autoimmune risk/bad irAEs @DanaFarber @MassGenBrigham: more RA flares but similar mortality, severe irAEs rates Give them what they need! ABST1667 @jeffsparks #ACR22 @RheumNow https://t.co/WdDP8IeIYG
Fletcher et al. Epidemiology RA-ILD 2004-18 in VA. Incidence increased from 340 to 970/100,000PY. Prevalence increased 1.7% to 4.5%. More common males (4.81% vs 2.53%) and over 60 @RheumNow #ACR22 Abstr#1638 https://t.co/AbPgLUPoDz https://t.co/V25xDUwLbu
Peresolimab PD-1 agonist in RA Phase 2 RCT Primary endpoint met w/ > improvement DAS28CRP Wk12 Also greater improvement of CDAI in both treated grps TEAEs PBO 37% PER 300mg 40% PER 700mg 35%, 1 serious AE in PER 700mghttps://t.co/QtclWIWAw9Abs#L03 #ACR22 @Rheumnow https://t.co/bLHP4JuNjt
×